Net efficacy adjusted for risk: further developments.
'Net efficacy adjusted for risk' (NEAR) is a simple quantitative indicator integrating risk and benefit in one measure. NEAR considers that, in a clinical trial (CT), the drug with the best risk:benefit profile corresponds to that causing the greatest number of patients to respond favourably without suffering adverse drug reactions. This number is only exceptionally reported; thus, a NEAR estimate is obtained by calculating expected frequencies. NEAR is designed to compare two drugs and may be expressed as odds ratio or relative risk with their 95% CIs. To analyse the influence of using either intention-to-treat (ITT) or per-protocol (PP) populations in NEAR results. The use of NEAR as 'effect size' in performing meta-analyses is posed. By analyzing several examples, differences between NEAR calculated by considering either ITT or PP populations are presented. Likewise, an example of meta-analysis by using NEAR as effect size is shown. NEAR results may be optimised by considering the type of population analysed, ITT or PP. Meta-analyses using NEAR as effect size provide new insights into CT results. Last, correcting certain deficits in adverse drug reactions reporting is required in CT risk assessment.